Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

Chr t(2;5)(p23;q35) NPM1/ALK

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EML4-ALK variant 3 + TP53 mutation (5)

ALK fusion + ALK G1202R (4)

TP53 mutation + ALK positive (4)

ALK rearrangement + MET amplification (3)

EGFR wild-type + ALK wild-type + PD-L1 expression (3)

EML4-ALK fusion + ALK F1174L + ALK S1189C (3)

EML4-ALK fusion + ALK positive (3)

PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)

RANBP2-ALK rearrangement + TNFRSF8 expression (3)

ALK fusion + TP53 mutation (2)

ALK positive + ALK mutation (2)

ALK rearrangement + PD-L1 overepxression (2)

EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)

EML4-ALK fusion + ALK G1202R (2)

EML4-ALK fusion + ALK rearrangement (2)

EML4-ALK fusion + TP53 mutation (2)

EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)

MYC amplification + ALK F1174L (2)

MYCN amplification + ALK F1174V (2)

MYCN amplification + ALK rearrangement (2)

STRN-ALK fusion + MET amplification (2)

ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)

ALK expression + RSRC1-ALK fusion (1)

ALK fusion + ALK G1269A (1)

ALK fusion + ALK I1179T (1)

ALK fusion + ALK V1180L (1)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)

ALK fusion + FAT3 mutation (1)

ALK fusion + FAT4 mutation (1)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK mutation + TMB-H (1)

ALK negative + S100A8 elevation (1)

ALK negative + S100A9 elevation (1)

ALK negative + SAA1 elevation (1)

ALK negative + SAA2 elevation (1)

ALK negative + TP53 deletion (1)

ALK positive + ALK G1202R (1)

ALK positive + ALK G1202R + ALK L1196M (1)

ALK positive + ALK L1196M + ALK D1203N (1)

ALK positive + DNMT3A N403Tfs* (1)

ALK positive + EML4-ALK fusion + TP53 mutation (1)

ALK positive + ERCC3 E259D + GNAS A436_P459del (1)

ALK positive + MYC amplification + CCND1 deletion (1)

ALK psoitive + ALK G1202R + ALK F1174C (1)

ALK rearrangement + ABCC11 overexpression (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

ALK rearrangement + BRCA2 F2801fs (1)

ALK rearrangement + CDKN2A deletion (1)

ALK rearrangement + CDKN2B deletion (1)

ALK rearrangement + CTLA4 overexpression (1)

ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)

ALK rearrangement + MET amplification (1)

ALK wild-type + NT5E overexpression + PD-L1 expression (1)

ALK-EML4_V3a + PD-L1 overexpression (1)

ALK-EML4_V3b + PD-L1 overexpression (1)

BCL2L11 deletion + ALK positive (1)

CPE-ALK fusion + TP53 wild-type (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + STRN-ALK fusion (1)

EGFR mutation + ALK negative + TMB-H (1)

EGFR negative + ALK negative + PD-L1 expression (1)

EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)

EML4-ALK fusion + ALK I1171N (1)

EML4-ALK fusion + ALK I1171T (1)

EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)

EML4-ALK fusion + TMB-L (1)

EML4-ALK fusion v1insLTBP1 (1)

IDH2 mutation + ALK fusion (1)

KIF5B-ALK fusion + ALK L1196M (1)

MET amplification + KLC1-ALK fusion (1)

MET exon 14 mutation + ALK wild-type (1)

MYCN amplification + ALK F1174L (1)

MYCN amplification + ALK R1275Q (1)

PIK3CA mutation + ALK fusion (1)

PIK3CA mutation + ALK positive (1)

PTEN mutation + ALK positive (1)

SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)

SMARCA4 mutation + ALK positive (1)

STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)

STRN-ALK fusion + KRAS G13D (1)

TMB-H + ALK rearrangement (1)

TPM3-NTRK1 fusion + ALK L1196M (1)

KMT2A rearrangement + NPM1 mutation (1)

PD-L1 underexpression + ALK wild-type (0)

EML4-ALK variant 3 + TP53 mutation (5)

ALK fusion + ALK G1202R (4)

TP53 mutation + ALK positive (4)

ALK rearrangement + MET amplification (3)

EGFR wild-type + ALK wild-type + PD-L1 expression (3)

EML4-ALK fusion + ALK F1174L + ALK S1189C (3)

EML4-ALK fusion + ALK positive (3)

PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)

RANBP2-ALK rearrangement + TNFRSF8 expression (3)

ALK fusion + TP53 mutation (2)

ALK positive + ALK mutation (2)

ALK rearrangement + PD-L1 overepxression (2)

EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)

EML4-ALK fusion + ALK G1202R (2)

EML4-ALK fusion + ALK rearrangement (2)

EML4-ALK fusion + TP53 mutation (2)

EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)

MYC amplification + ALK F1174L (2)

MYCN amplification + ALK F1174V (2)

MYCN amplification + ALK rearrangement (2)

STRN-ALK fusion + MET amplification (2)

ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)

ALK expression + RSRC1-ALK fusion (1)

ALK fusion + ALK G1269A (1)

ALK fusion + ALK I1179T (1)

ALK fusion + ALK V1180L (1)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)

ALK fusion + FAT3 mutation (1)

ALK fusion + FAT4 mutation (1)

ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)

ALK mutation + TMB-H (1)

ALK negative + S100A8 elevation (1)

ALK negative + S100A9 elevation (1)

ALK negative + SAA1 elevation (1)

ALK negative + SAA2 elevation (1)

ALK negative + TP53 deletion (1)

ALK positive + ALK G1202R (1)

ALK positive + ALK G1202R + ALK L1196M (1)

ALK positive + ALK L1196M + ALK D1203N (1)

ALK positive + DNMT3A N403Tfs* (1)

ALK positive + EML4-ALK fusion + TP53 mutation (1)

ALK positive + ERCC3 E259D + GNAS A436_P459del (1)

ALK positive + MYC amplification + CCND1 deletion (1)

ALK psoitive + ALK G1202R + ALK F1174C (1)

ALK rearrangement + ABCC11 overexpression (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

ALK rearrangement + BRCA2 F2801fs (1)

ALK rearrangement + CDKN2A deletion (1)

ALK rearrangement + CDKN2B deletion (1)

ALK rearrangement + CTLA4 overexpression (1)

ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)

ALK rearrangement + MET amplification (1)

ALK wild-type + NT5E overexpression + PD-L1 expression (1)

ALK-EML4_V3a + PD-L1 overexpression (1)

ALK-EML4_V3b + PD-L1 overexpression (1)

BCL2L11 deletion + ALK positive (1)

CPE-ALK fusion + TP53 wild-type (1)

EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)

EGFR exon 19 deletion + STRN-ALK fusion (1)

EGFR mutation + ALK negative + TMB-H (1)

EGFR negative + ALK negative + PD-L1 expression (1)

EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)

EML4-ALK fusion + ALK I1171N (1)

EML4-ALK fusion + ALK I1171T (1)

EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)

EML4-ALK fusion + TMB-L (1)

EML4-ALK fusion v1insLTBP1 (1)

IDH2 mutation + ALK fusion (1)

KIF5B-ALK fusion + ALK L1196M (1)

MET amplification + KLC1-ALK fusion (1)

MET exon 14 mutation + ALK wild-type (1)

MYCN amplification + ALK F1174L (1)

MYCN amplification + ALK R1275Q (1)

PIK3CA mutation + ALK fusion (1)

PIK3CA mutation + ALK positive (1)

PTEN mutation + ALK positive (1)

SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)

SMARCA4 mutation + ALK positive (1)

STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)

STRN-ALK fusion + KRAS G13D (1)

TMB-H + ALK rearrangement (1)

TPM3-NTRK1 fusion + ALK L1196M (1)

KMT2A rearrangement + NPM1 mutation (1)

PD-L1 underexpression + ALK wild-type (0)

›

4years

Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein. (PubMed, Sci Rep)

64 million molecules or 4.5 pg per lymphocyte). We also compared NPM-ALK/ β-actin ratios determined by ELISA to those independently determined by two-dimensional electrophoresis and showed that the two methods are in good agreement.

4 years ago

Journal

|

ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1)

|

ALK fusion • ALK translocation • Chr t(2;5)(p23;q35) NPM1/ALK